Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nogapendekin alfa inbakicept + CD19 t-haNK
- Development stage
- Unknown
- Lead developer
- ImmunityBio
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
ANKTIVA + CD19 t-haNK is a combination immunotherapy being developed by ImmunityBio (formerly NantCell/NantKwest) for the treatment of CD19-expressing B-cell malignancies, including relapsed/refractory Non-Hodgkin Lymphoma. The combination consists of **ANKTIVA** (nogapendekin alfa inbakicept), an IL-15 superagonist fusion protein, and **CD19 t-haNK**, an off-the-shelf, allogeneic NK-92-based cell therapy. ANKTIVA is designed to stimulate the proliferation and activation of NK cells and T cells by targeting the IL-15 receptor complex. CD19 t-haNK cells are genetically engineered to express a CD19-specific chimeric antigen receptor (CAR) for direct tumor targeting and a high-affinity CD16 (FcγRIIIa 158V) receptor to enhance antibody-dependent cellular cytotoxicity (ADCC). This dual-action approach combines cytokine-driven immune stimulation with targeted cellular cytotoxicity to overcome resistance in refractory lymphoma patients.
- Other names
- nogapendekin-alfa inbakiceptCD19-targeted high-affinity natural killer cell therapyCD-19-targeted high-affinity natural killer cell therapyCD 19-targeted high-affinity natural killer cell therapyN-803 + CD19 t-haNK
02
Targets
CD19 (B lymphocyte antigen CD19)IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)FcγRIIIa (Low affinity immunoglobulin gamma Fc region receptor III-A)
Beyond the preview
Go deeper on nogapendekin alfa inbakicept + CD19 t-haNK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nogapendekin alfa inbakicept + CD19 t-haNK.